BioPorto

Board/Management Information • Jan 6, 2015

Mr. Otto Rasmussen will step down as CFO of BioPorto A/S at January 31, 2015 to
become Finance Director of Xellia Pharmaceuticals, a company owned by Novo A/S.

Peter Mørch Eriksen, CEO of BioPorto, said: “Otto has been an important part of
the first phase of BioPorto’s turnaround, building a solid finance department
and streamlining business procedures. With a strong capital base and fully
functional back-office, we now turn our attention to the commercialization of
our diagnostic tests and antibodies. Therefore, Otto has decided it was time to
take on new challenges. I would like to thank him for our great cooperation in
BioPorto and wish him good luck in his new position at Xellia.”

Mrs. Birgitte Svendsen has been appointed interim CFO of BioPorto from February
1, 2015. Birgitte is a former accountant at Arthur Andersen and has previously
also held positions as controller and financial director in companies like Novo
Nordisk, Carat Danmark and Tiscali/World Online. Today, Birgitte is partner and
CEO of Pecunia Consult.

Going forward, the executive management at BioPorto A/S will be constituted by
Peter Mørch Eriksen, CEO.

The above changes to the executive management does not affect revenue and
earnings guidance announced by BioPorto for the 2014 financial year.

Further details:

Peter Mørch Eriksen, CEO

Tel.: 45 29 00 00, e-mail investor@bioporto.com

About BioPorto

BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides
healthcare professionals in clinical and research settings with a range of
diagnostic tests and antibodies. Our pioneering product portfolio includes
assays for underdiagnosed diseases, including NGAL test for acute kidney
injury. We sell our products in more than 80 countries through diverse sales
channels and partners. BioPorto is headquartered in Copenhagen, Denmark and is
listed on the NASDAQ Copenhagen stock exchange.